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Abstract
Rationale Evidence suggests that depression is cross-
sectionally and longitudinally associated with activation of
inflammatory response system. A few studies, however, have
investigated the longitudinal relationship between raised in-
flammatory biomarkers and persistence of depressive symp-
toms. We examined the temporal relationship between serum
levels of inflammatory biomarkers and persistence of depres-
sive symptoms among older participants.
Methods Center for Epidemiologic Studies Depression Scale
(CES-D) was used to assess depressive symptoms at baseline
and at 5-year follow-up in 656 participants (233 men, 423
women) aged >60 years of the Rotterdam Study. Markers of
inflammation interleukin (IL)-6, alpha-1-antichymotrypsin
(ACT) and C-reactive protein (CRP) were assessed at base-
line, and all participants taking antidepressant medications
were excluded from the analysis.
Results No cross-sectional association was found between IL-
6, ACTand CRPwith depressive symptoms at baseline. How-
ever, higher levels of IL-6 and CRP predicted depressive
symptoms at 5-year follow-up. Adjustment for confounding
variables had no impact on the observed associations. Simi-
larly, a positive association was found between baseline levels
of IL-6 (OR=2.44, p=0.030) and CRP (OR=1.81, p=0.052)
and persistence of depressive symptoms over 5 years.
Conclusion Our data suggest that dysregulation of the inflam-
matory response system is associated with a more severe form
of depression more likely to re-occur.
Keywords Mood disorder . Pro-inflammatory cytokines .
Chronic illness . Epidemiological . Psychosomatic . Aging
Introduction
There is evidence implicating inflammation as a potential eti-
ologic factor for mood disorders. Meta-analysis studies have
reported higher levels of inflammatory cytokines (such as in-
terleukin-6, (IL-6)) and acute phase proteins (such as C-
reactive protein (CRP)) in the peripheral blood and cerebro-
spinal fluid of patients with major depression (Dowlati et al.
2010; Howren et al. 2009). In addition, inflammation and
depressive symptoms seem to be associated in large epidemi-
ological cross-sectional studies (Liu et al. 2014; Matthews
et al. 2010; van den Biggelaar et al. 2007).
Further evidence stems from prospective studies showing
that acute or chronic administration of cytokines leads to de-
velopment of depressive symptoms. Chronic administration
of the pro-inflammatory cytokine interferon-alpha (IFN-α)
for treatment of hepatitis C induced clinically significant de-
pression in 30–50 % of persons with no psychiatric disorders
previous to interferon-alpha (IFN-α) treatment (Alavi et al.
2012; Birerdinc et al. 2012). Additional evidence to support
an association between elevated immune-inflammatory cyto-
kines and depressive-like behavioural systems is provided in
animal models. Elevated immune-inflammatory cytokines in-
duce and exacerbate depressive-like symptoms, whereas tu-
mour necrosis factor-alpha (TNF)-α and IL-6 receptor
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knockout mice show reduced behavioural indices of depres-
sion (Chourbaji et al. 2006; Dantzer 2001; Dantzer et al. 2008;
Felger et al. 2007; McNamara and Lotrich 2012; Simen et al.
2006). In humans, fewer large epidemiological studies point
towards a possible association between activation of inflam-
matory system and future depressive symptoms (Valkanova
et al. 2013; van den Biggelaar et al. 2007; Wium-Andersen
et al. 2013), although controversy still exists (Stewart et al.
2009).
A possible explanation for this controversy is the hypothe-
sis that activation of the inflammatory system distinguishes a
particular subset of patients, i.e. those who have a more severe
form of depression. In agreement, an activation of the inflam-
matory system was particularly observed in major depressive
patients who are older (Grosse et al. 2014); have recurrent
episodes (Ford and Erlinger 2004; Grosse et al. 2014); have
comorbid depression with other mental and physical illnesses
(Jones et al. 2004; Liukkonen et al. 2011; Moussavi et al.
2007); present earlier onset of the disorder (Grosse et al.
2014) and are resistant to antidepressant treatment (Carvalho
et al. 2008, 2014). Consistent with the hypothesis that inflam-
mation is present in a particular subgroup of depressed pa-
tients, the anti-inflammatory drug infliximab showed antide-
pressant properties only in treatment-resistant depressed pa-
tients who have high levels of the inflammatory marker C-
reactive protein (Raison et al. 2013).
In this study, we take a longitudinal approach to examine
the temporal relationship between the inflammatory bio-
markers IL-6, alpha-1-antichymotrypsin (ACT) and CRP at
baseline and incident depressive symptoms 5 years later or
persistent depressive symptoms over 5 years. Participants tak-
ing antidepressant medications were excluded from the anal-
ysis due to the small population size.
Methods
Study population
The present study is embedded within the Rotterdam Study, a
population-based cohort study in which all inhabitants age 55
and over living in a defined geographic area of Rotterdam
have been invited to participate (Hofman et al. 1991). The
Medical Ethics Committee approved the study according to
the Wet Bevolkingsonderzoek: ERGO (Population Study Act:
Rotterdam Study) executed by theMinistry of Health, Welfare
and Sports of the Netherlands. Written informed consent was
obtained from all participants. During the third survey (1997–
1999), participants were assessed for depressive symptoms.
For the present study, of the 3571 persons who were screened
for depressive symptoms, only 1211 had available informa-
tion on serum level of inflammatory biomarkers. Moreover,
37 participants were excluded for being on antidepressants,
leaving 1175 participants eligible for analysis. In the present
analysis, we studied the association of inflammatory proteins
and depressive symptoms in 656 participants free of antide-
pressant medications. Out of these participants, 102 were on
anti-inflammatory medications. In this study, we do not have
repeated measures of inflammatory cytokines (IL-6, ACT and
CRP) and therefore could not analyse whether long-term ex-
posure to high levels of inflammatory markers are associated
with depression. Sequential exclusions occurred according to
the flow chart represented in Fig. 1.
Depression assessment
Depressive symptoms were assessed through participant’s
completion of the Dutch version of the original Center for
Epidemiological Studies Depression Scale (CES-D) during a
home interview (Beekman et al. 1997; Luijendijk et al. 2008).
The CES-D is a self-reporting 20-item measure of depressive
symptoms scored on a scale from 0 to 3. For the analysis of
persistent depressive symptoms, we used a score of 16 as a
cut-off, to indicate clinically significant depressive symptoms
in each wave (Beekman et al. 1997; Blazer et al. 1991). Per-
sistent depressive symptoms were defined by having CES-D
scores ≥16 in 1997–1999 (baseline) and when re-assessed in
2002–2004 (follow-up).
Blood specimens
At baseline, a venipuncture was performed by application of
minimal stasis with a 21-gauge butterfly needle with tube
(Surflo winged infusion set, Terumo). Fasting blood was col-
lected in the morning, and all tubes were put on ice directly
and centrifuged at 2000×g for 10 min. Plasma was separated
and dispensed into two 1.5-mL aliquots and then frozen with-
in 3 h at −80 °C. Both ACTand CRP were assessed by means
of a nephelometric method (BN 100, Dade Behring, Marburg,
Germany). The IL-6 concentrations were determined with
quantitative enzyme-linked immunosorbent assay with a test
kit from R&D systems (Minneapolis, MN). The intra-assay
and inter-assay coefficients for all measurements were <5 and
<8 %, respectively. High-sensitivity CRP was measured in a
serum, which was stored at −20 °C until performance of the
CRP measurements, using a rate near-infrared particle immu-
noassay (IMMAGE, Immunochemistry System, Beckman
Coulter, San Diego, CA, detection limit 0.2 mg/L, coefficient
of variation (CV) 3.2 %). In this matter, a fully automated
Hitachi 747 system (Hitachi, Tokyo, Japan, detection limit
1 mg/L, CV <5 %) was used. IL-6 plasma levels were deter-
mined using a quantitative enzyme-linked immunosorbent as-
say (ELISA) technique (Quantikine HS IL-6 kit, R&D Sys-
tems, Oxon, UK, detection limit 0.094 pg/mL, CV 8.7 %) and
ACT plasma levels using kinetic nephelometry (Behring
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Nephelometer BN200, Marburg, Germany, detection limit
1.5 mg/dL, CV 2.8 %).
Other measurements
The following variables were considered as possible con-
founding variables: age, sex, education (low, middle,
high), physical illness (including prevalent stroke, cardio-
vascular disease and diabetes), cognitive function (as
measured by the mini-mental state examination), smoking
and body mass index (BMI). A history of stroke was
obtained through direct questioning and computerized
linkage with general practitioner medical records (Ikram
et al. 2008). Smoking was coded as number of cigarettes
currently smoked per day and in categories of current,
former and never smoker. To exclude for obvious signs
of inflammation when we analysed IL-6 and ACT, we
adjusted for acute inflammation as defined by C-reactive
protein level >10 mg/L. BMI was defined by >18.50 kg/
m2 unde rwe igh t , 18 . 50–24 . 99 kg /m2 no rma l ,
25–29.99 kg/m2 overweight and >30 kg/m2 obese.
Statistical analysis
All data analysis was performed with IBM SPSS Statistics
22. We normalized the distribution of IL-6, ACT and CRP
by natural logarithmic transformation and used binary lo-
gistic regression to estimate the odds ratio (OR) and 95 %
confidence intervals (CIs) of inflammatory markers for
depressive symptoms at baseline (1997–1999). To assess
the association between the log of the mean IL-6, ACT,
CRP and depressive symptoms at 5-year follow-up, we
performed linear regression analysis of the CES-D scores
at 5-year follow-up (2002–2004) with adjustment for de-
pressive symptoms at baseline (1997–1999). To further
explore the association between inflammatory proteins
and persistent depressive symptoms over the 5 years
(1997/1999–2002/2004), multinomial binary logistic anal-
ysis were performed using the CES-D scores (≥16) at
baseline and at 5-year follow-up.
Age (continuous) and sex were controlled for in all analy-
ses. To further analyse the effect of confounding factors, we
added potential confounders to the basic model. If this
changed the effect estimate meaningfully, the contribution of
each variable was individually explored. In subgroup analy-
ses, we assessed the age- and sex-adjusted association follow-
ing exclusion of participants with acute inflammation or those
with low mini-mental state examination (MMSE) scores.
Results
Demographic characteristics
Table 1 represents information on socio-demographic and
clinical baseline characteristics of the participants. The aver-
age age of the study participants was 73 years (range 61.1–
105.8); 59.9 % of whom were women. Among the study par-
ticipants, the majority was either classified as being over-
weight or obese (65.3 %). Most participants were past
smokers 48.4 %. Only the minority of participants reported
history of physical illness (34 %) or were screened positive for
cognitive impairment (13.7 %). Mean scores of levels of pro-
inflammatory biomarkers in study participants are reported.
No association of IL-6, ACT or CRP and depressive
symptoms at baseline
To determine if there was a cross-sectional relationship be-
tween serum levels of inflammatory biomarkers IL-6, ACT
or CRP and current depressive symptoms at baseline, we per-
formed logistic regression analysis with CES-D scores at
Fig. 1 Flow chart for sample
selection in the study
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baseline. Our data indicate no association between inflamma-
tory proteins IL-6 (OR=1.08; p=0.731), ACT (OR=1.069;
p=0.670) and CRP (OR=0.851; p=0.819) and current de-
pressive symptoms at baseline following adjustment for age
and gender.
IL-6 and CRP predict depressive symptoms at 5-year
follow-up in older people
To investigate if inflammatory markers are predictive of de-
pressive symptoms at 5-year follow-up, stepwise linear re-
gression were performed with the CES-D scores at 5-year
follow-up (Table 2). In our basic model, we corrected for
age, gender and depressive symptoms at baseline. Subse-
quently, corrections included acute inflammation, socio-
demographic and health characteristics. Our data indicate that
IL-6 (B=0.084, p=0.016) and CRP (B=0.086, p=0.013) were
significant predictors of depressive symptoms at 5-year fol-
low-up and remained so after correction for all socio-
demographic and health characteristics. ACT (B=0.057, p=
0.083) showed a trend association with depressive symptoms
at 5-year follow-up, following adjustment for age, gender and
depressive symptoms at baseline. The trend association for
ACT disappeared after correcting for additional socio-
demographic and health characteristics including BMI,
smoking, physical illness, low MMSE scores and acute in-
flammation (Table 2).
The contribution of individual covariates
in the association between inflammatory markers
and depressive symptoms at 5-year follow-up
Association with IL-6 or CRP
In the secondary analysis, we included adjustments for indi-
vidual covariates to further assess the effect of each variable
on the association between inflammatory markers at baseline
and depressive symptoms at 5-year follow-up (Tables 3 and
4). Our results indicate that the association between the levels
of IL-6 or CRP and depressive symptoms remained strong and
was not substantially affected by age, gender, BMI, smoking
status, physical illness, low MMSE scores or acute inflamma-
tion (specific to IL-6 analysis only), when adjusted individu-
ally or in combination. As acute inflammation was calculated
as CRP >10 mg/mL, no adjustment for acute inflammation
could be done when CRP was used as a predictor.
In the IL-6 subgroup, exclusion of participants with acute
inflammation (B=0.089, p=0.010) or low MMSE scores (B=
Table 1 Demographic
characteristics of participants in
Rotterdam Study
Demographics Characteristics
Age (years) (mean, range) 73 (61–106)
Gender (%)
Male 40.1
Female 59.9
Education (%) Low 61.2
Middle 29.1
High 9.7
BMI (kg/m2)
>18.50 0.9
18.50–24.99 33.8
25–29.99 46.4
30–40 18.9
Smoking status (%)
Non-smoker 35.2
Past smoker 48.4
Current smoker 16.4
History of physical illness (%) 34
MMSE score (%)
>26 13.7
≤26 86.3
Interleukin-6 (pg/mL) 4.07 (0.53–80)
α1-Antichymotrypsin (mg/dL) 40.3 (19.5–128.5)
C-Reactive protein (mg/L) 3.39 (0.06–88.8)
BMI bodymass index, physical illness stroke, history of cardiovascular disease and diabetes,MMSEmini-mental
state examination, IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein
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0.170, p=0.001) did not alter the significance of the associa-
tion between levels of IL-6 and depressive symptoms at 5-year
follow-up (Table 3).
Similarly, in the fully adjusted model, IL-6 predicted incident
depressive symptoms after 5 years following exclusion of CRP
values >10 mg/L (full model: B=0.089, p=0.013, n=622).
In contrast to IL-6, the association between levels of CRP
and incident depressive symptomswas no longer observed (full
model: B=0.044, p=0.223, n=622) following exclusion of
subjects with CRP values >10 mg/L and adjustment of all
covariates.
Similarly to IL-6, in the CRP subgroup, exclusion of par-
ticipants with low MMSE scores (B=0.108, p=0.008) did not
affect the association between CRP levels and depressive
symptoms (Table 4). Our data reported no significant gender
and IL-6 or CRP interaction in the prediction of depressive
symptoms at 5-year follow-up (following adjustment for age);
thus, no further analysis stratified for gender was performed.
Association with ACT
As no association was found between ACT and depressive
symptoms at 5-year follow-up, no further analysis was
conducted.
IL-6 and CRP are associated with persistent depressive
symptoms over 5 years
To investigate whether there was any association between
inflammatory proteins and persistent depressive symptoms
over 5 years, we generated cut-off scores CES-D ≥16 at base-
line and at 5-year follow-up and subsequently performed lo-
gistic analysis. In the basic model 1, IL-6 (OR=2.32, p=
0.035) and CRP (OR=1.79, p=0.043) were positively associ-
ated with persistent depressive symptoms over 5 years
Table 2 The association between inflammatory proteins and
depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) P value
Log IL-6 (per 1 SD increment)α
Model 1 656 0.107 (1.32, 5.38) 0.001
Model 2 650 0.105 (1.16, 5.33) 0.002
Model 3 650 0.084 (0.48, 4.73) 0.016
Log ACT (per 1 SD increment)α
Model 1 655 0.057 (−0.67, 10.76) 0.083
Model 2 650 0.048 (−1.57, 10.04) 0.153
Model 3 650 0.020 (−4.20, 7.75) 0.561
Log CRP (per 1 SD increment)α
Model 1 656 0.090 (0.55, 3.19) 0.006
Model 2 650 0.086 (0.38, 3.16) 0.013
The category Bdepressive symptoms^ includes all subjects who were
screened positive. α=levels of inflammatory biomarkers from measure-
ments of 1997–1999: new onset of depressive symptoms at 5-year fol-
low-up in participants with no depressive symptoms at baseline. Subjects
on antidepressant medications were excluded from the analysis.Model 1
linear regression analysis adjusted for age and gender.Model 2 as model 1
and additionally adjusted for body mass index (BMI), smoking, physical
illness (including stroke, history of cardiovascular disease and diabetes)
and mini-mental state examination (MMSE). Model 3 as model 2 and
additionally adjusted for acute inflammation. No model 3 was created for
CRP as acute inflammation was calculated as CRP >10 mg/mL; there-
fore, no adjustment for acute inflammation could be done when CRP was
used as a predictor
IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein,
SD standard deviation, B standardized beta, CI confidence interval
Table 3 The association between levels of IL-6 and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) P value
Log IL-6 (per 1 SD increment)α
Age, sex 656 0.107 (1.32, 5.38) 0.001
Age, sex, BMI (kg/m2) 652 0.109 (1.31, 5.46) 0.001
Age, sex, smoking status 656 0.105 (1.24, 5.32) 0.002
Age, sex, physical illness 656 0.106 (1.26, 5.34) 0.002
Age, sex, MMSE 654 0.106 (1.27, 5.33) 0.002
Age, sex, acute inflammation 656 0.088 (0.68, 4.83) 0.009
Fully adjusted* 650 0.084 (0.48, 4.73) 0.016
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 627 0.089 (0.68, 4.91) 0.010
Excluding those with MMSE 416 0.170 (2.99, 8.12) 0.001
Individual contribution of each covariate
The category Bdepressive symptoms^ includes all subjects who were screened positive. α = levels of IL-6 from measurements of 1997–1999: new onset
of depressive symptoms at 5-year follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant medications were
excluded from the analysis
IL-6 interleukin-6, SD standard deviation, B standardized beta, CI confidence interval, BMI body mass index, MMSE mini-mental state examination
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(Table 5). In model 2, this association remained relatively
unchanged after adjusting for age, gender, BMI, smoking
status, physical illness and low MMSE scores for IL-6
(OR=2.44, p=0.03) and CRP (OR=1.81, p=0.052), re-
spectively. In contrast to the previous observations on
the depressive symptoms at 5-year follow-up (incident
depression, Table 2), acute inflammation largely
explained the association between IL-6 and persistent de-
pressive symptoms in the fully adjusted model 3 (OR=
2.02, p=0.107) (Table 5). Levels of ACT (OR=1.38, p=
0.80) were not positively associated with persistent de-
pressive symptoms following adjustment for age and gen-
der. No gender interaction was found for IL-6, ACT or
CRP in the prediction of persistence depressive symptoms
over 5 years following adjustment for age; thus, no further
analysis stratified for gender was performed.
The contribution of individual covariates
on the association between levels of IL-6 or CRP
and persistent depressive symptoms over 5 years
Association with IL-6 or CRP
We further investigated whether the individual covariates
could explain the correlation between IL-6 or CRP and
persistent depressive symptoms during the 5 years
(Tables 6 and 7). Our results indicate that the association
between the levels of IL-6 and persistent depressive
symptoms was little explained by age, gender, BMI,
smoking status, physical illness or MMSE, when adjusted
individually. In contrast, acute inflammation largely ex-
plained the association between the levels of IL-6 and
persistent depressive symptoms. Indeed correcting for
(OR=1.96, p=0.113) or excluding (OR=2.19, p=0.068)
participants with acute inflammation reduced this associ-
ation to insignificant levels (Table 6).
However, IL-6 predicted persistent depressive symptoms
following exclusion of CRP values >10 mg/L and adjustment
of all covariates (full model: OR=2.37, p=0.049, n=622).
In contrast, the association between CRP levels and persis-
tent depressive symptoms was no longer observed following
Table 4 The association between
levels of CRP and depressive
symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) P value
Log CRP (per 1 SD increment)α
Age, sex 656 0.090 (0.55, 3.19) 0.006
Age, sex, BMI (kg/m2) 652 0.090 (0.46, 3.23) 0.009
Age, sex, smoking status 656 0.088 (0.50, 3.15) 0.007
Age, sex, physical illness 656 0.089 (0.51, 3.16) 0.007
Age, sex, MMSE 654 0.089 (0.53, 3.16) 0.006
Fully adjusted* 650 0.086 (0.38, 3.16) 0.013
Subgroups (age and sex adjusted)
Excluding those with MMSE 416 0.108 (0.63, 4.06) 0.008
Individual contribution of each covariate
The category Bdepressive symptoms^ includes all subjects who were screened positive. α = levels of CRP from
measurements of 1997–1999: new onset of depressive symptoms at 5-year follow-up in participants with no
depressive symptoms at baseline. Subjects on antidepressant medications were excluded from the analysis
CRP C-reactive protein, SD standard deviation, B standardized beta, CI confidence interval, BMI body mass
index, MMSE mini-mental state examination
Table 5 The association between inflammatory proteins and persistent
depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) P value
Log IL-6
Model 1 656 2.32 (1.06, 5.06) 0.035
Model 2 650 2.44 (1.09, 5.45) 0.030
Model 3 649 2.02 (0.86, 4.77) 0.107
Log ACT
Model 1 654 1.38 (0.12, 16.06) 0.80
Model 2 649 1.23 (0.09, 15.27) 0.871
Model 3 649 0.63 (0.045, 8.81) 0.729
Log CRP
Model 1 655 1.79 (1.02, 3.13) 0.043
Model 2 649 1.81 (0.99, 3.29) 0.052
The category Bdepressive symptoms^ includes all subjects who were
screened positive: CES-D ≥16 at baseline and at 5-year follow-up. Sub-
jects on antidepressant medications were excluded from the analysis.
Model 1 multinomial binary logistic regression analysis adjusted for age
and gender.Model 2 as model 1 and additionally adjusted for body mass
index (BMI), smoking, physical illness (including stroke, history of car-
diovascular disease and diabetes) and mini-mental state examination
(MMSE).Model 3 as model 2 and additionally adjusted for acute inflam-
mation. No model 3 was created for CRP as acute inflammation was
calculated as CRP > 10 mg/mL; therefore, no adjustment for acute in-
flammation could be done when CRP was used as a predictor
IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein,
CI confidence interval
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exclusion of subjects with CRP values >10 mg/L (full model:
OR=1.45, p=0.310, n=621). The data suggest that the asso-
ciation between depression and inflammation seems to be
stronger for IL-6 than CRP.
In the subgroup analysis, exclusion of participants with
low MMSE scores (OR=2.64, p=0.046) did not affect the
positive relationship between levels of IL-6 and persistent
depressive symptoms (Table 6). In contrast to IL-6,
the association between levels of CRP and persistent de-
pressive symptoms over 5 years was largely explained by
adjustment for physical illness (OR=1.70, p=0.067) and
by exclusion (OR=1.68, p=0.138) but not adjustment for
low MMSE scores (OR=1.80, p=0.042) (Table 7). Asso-
ciation between CRP and depressive symptoms was little
explained by age, gender, BMI or smoking status.
Association with ACT
As no association was found between ACT and persistent
depressive symptoms over 5 years, no further analysis were
conducted.
Discussion
In this large population-based study of elderly persons, we
found that the inflammatory biomarkers IL-6 and CRP were
longitudinally associated with depressive symptoms. Both IL-
6 and CRP levels predicted persistent depressive symptoms
over 5 years independently of age, gender, BMI, smoking
status or MMSE. Furthermore, we found that IL-6 and CRP
Table 6 The association between levels of IL-6 and persistent depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) P value
Log IL-6
Age, sex 656 2.32 (1.06, 5.06) 0.035
Age, sex, BMI (kg/m2) 652 2.54 (1.15, 5.60) 0.021
Age, sex, smoking status 656 2.28 (1.04, 5.00) 0.040
Age, sex, physical illness 656 2.23 (1.01, 4.93) 0.048
Age, sex, MMSE 654 2.38 (1.09, 5.18) 0.030
Age, sex, acute inflammation 655 1.96 (0.85, 4.50) 0.113
Fully adjusted* 649 2.02 (0.86, 4.77) 0.107
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 626 2.19 (0.94, 5.01) 0.068
Excluding those with MMSE 416 2.64 (1.02, 6.88) 0.046
Individual contribution of each covariate
The category Bdepressive symptoms^ includes all subjects who were screened positive: CES-D ≥16 at baseline and at 5-year follow-up. Subjects on
antidepressant medications were excluded from the analysis
IL-6 interleukin-6, CI confidence interval, BMI body mass index, MMSE mini-mental state examination
Table 7 The association between
levels of CRP and persistent
depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) P value
Log CRP
Age, sex 655 1.79 (1.02, 3.13) 0.043
Age, sex, BMI (kg/m2) 651 1.93 (1.07, 3.49) 0.03
Age, sex, smoking status 655 1.76 (1.01, 3.09) 0.048
Age, sex, physical illness 655 1.70 (0.97, 2.98) 0.067
Age, sex, MMSE 653 1.80 (1.02, 3.16) 0.042
Fully adjusted* 649 1.81 (0.99, 3.29) 0.052
Subgroups (age and sex adjusted)
Excluding those with MMSE 415 1.68 (0.85, 3.35) 0.138
Individual contribution of each covariate
The category Bdepressive symptoms^ includes all subjects who were screened positive: CES-D ≥16 at baseline
and at 5-year follow-up. Subjects on antidepressant medications were excluded from the analysis
CRP C-reactive protein, CI confidence interval, BMI body mass index, MMSE mini-mental state examination
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predicted incident depressive symptoms at 5-year follow-up
after adjustment for all socio-demographic and health charac-
teristics. In contrast, no longitudinal association was observed
between the levels of ACTand depressive symptoms. None of
the inflammatory biomarkers were associated with depressive
symptoms at baseline in the cross-sectional analysis.
To the best of our knowledge, this is the first population-
based study to investigate whether inflammation predicts per-
sistent depressive symptoms over 5 years. Persistent depres-
sive symptoms and inflammation had been previously associ-
ated in a small study in individuals who were at high risk for
coronary heart disease (Azar et al. 2012). Our results are con-
sistent with the literature suggesting that activation of inflam-
matory response system contributes significantly to the main-
tenance of symptoms of depression and might be more rele-
vant in people who are more severely ill. Inflammation is
particularly observed in major depressive patients who are
older (Grosse et al. 2014), have comorbid depression with
physical (Jones et al. 2004; Moussavi et al. 2007) and mental
illnesses (Liukkonen et al. 2011), present recurrent (Ford and
Erlinger 2004) or earlier age of onset of the disorder (Grosse
et al. 2014) and in those who are resistant to antidepressant
treatment (Carvalho et al. 2008, 2014). Consistent with this
hypothesis, we found that the association between inflamma-
tion and persistent depression is lost when adjusted for phys-
ical illnesses. It is possible that inflammation distinguishes a
subgroup of depressed patients. In line with this idea, Raison
et al. showed that the anti-inflammatory drug infliximab
showed antidepressant properties only in treatment-resistant
depressed patients who have high levels of the inflammatory
marker C-reactive protein (Raison et al. 2013).
Secondly, in this study, we report a positive longitudinal
relationship between IL-6 or CRP levels and incident depres-
sive symptoms at 5-year follow-up. Our data is consistent with
findings from previous literature, which demonstrated a posi-
tive longitudinal association between inflammation and inci-
dent mental health. Similar to our study, Gimeno et al. found a
positive association between CRP, IL-6 and incident depres-
sive symptoms in healthy participants (Gimeno et al. 2009).
However, in their research, only cognitive depressive symp-
toms were reported, and mental health was conducted by
using the general health questionnaire (GHQ) which is less
specific for depressive symptoms. In our study, depressive
symptoms were measured using the CES-D scale which is
reported to have an excellent sensitivity (100 %) and specific-
ity (88 %) for major depression in a community-based sample
of older subjects (Beekman et al. 1997). Also, in agreement
with the present results, Kivimaki et al. showed that persistent
elevation of IL-6 levels increases risk of common mental dis-
order (Kivimaki et al. 2014). Likewise, van den Biggelaar and
colleagues showed that baseline levels of CRP significantly
predicted incident depression at 5-year follow-up in elderly
participants of >85 years old (van den Biggelaar et al. 2007).
Further investigations on the link between inflammation
and incident depression have also been conducted in different
population groups compared to ours. For example, it has been
reported that inflammation also predicts depression in females
after an accident (Matheny et al. 2011) and in middle-aged
adults (Matthews et al. 2010) but not in younger adults
(Deverts et al. 2010; Stewart et al. 2009).
This study does not report a cross-sectional association
between inflammatory biomarkers and depressive symptoms
at baseline. Our data is consistent with findings from Matsu-
shima et al. who reported no cross-sectional association be-
tween baseline values of hsCRP and IL-6 and depressive
symptoms in a community-dwelling older participants (Ma-
tsushima et al. 2015). Our data is also consistent with that of
Krogh et al. who showed no cross-sectional association be-
tween hsCRP and IL-6 levels and depressive symptoms in
people with depression (Krogh et al. 2014). The fact that no
cross-sectional association was found suggests that the re-
sponse to peripheral infection on producing inflammatory cy-
tokines that act on the brain to cause depression might occur
only when this inflammatory stimuli is persistent and might
not occur in a normal acute and transitional response of the
inflammatory system (Dantzer et al. 2008).
Several mechanisms have been speculated on how inflam-
mation and depression may be associated. Both clinical and
experimental data strongly point toward the involvement of
the enzyme indoleamine 2,3 dioxygenase in the development
of inflammation-associated major depressive disorders
(Dantzer e t a l . 2008) . Reduced funct ion of the
hypothalamus-pituitary-adrenal (HPA) axis has been observed
in the presence of chronic inflammation in severely ill patients
with major depression (Carvalho et al. 2008, 2014). Inflam-
mation also induces a reduction in the brain-derived neuro-
trophic factor (BDNF), which negatively influences
neurogenesis and neuroplasticity (Cortese et al. 2011; Felger
and Lotrich 2013; Lotrich et al. 2013). Over time, a decrease
in neurogenesis could contribute to the reduction in hippo-
campal volume seen in major depression (Campbell and
Macqueen 2004) and cognitive dysfunction (Hoglinger et al.
2004) which is positively correlated with a longer duration of
depressive symptoms in the community (Beekman et al.
2002). Furthermore, it has been suggested that pro-
inflammatory cytokines can modulate the tryptophan/
kynurenine pathway and decrease tryptophan availability for
serotonin synthesis (Dantzer et al. 2008; Felger and Lotrich
2013; Raedler 2011).
We did not find a longitudinal association between levels of
ACT and depressive symptoms. Our findings seem surprising
because ACT is an acute phase serum glycoprotein, which is
positively associated with CRP (Schaap et al. 2006). A possi-
ble explanation for this could be that ACT is a less sensitive
marker for inflammation than CRP, which signals early in-
flammation when other clinical parameters are yet unchanged,
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and therefore, the latter reveals early inflammation when other
clinical parameters are equivocal (Becking et al. 2013; Chard
et al. 1988; Lu et al. 2013).
This study has several strengths. First, the assessment of
depressive symptoms at baseline and at 5-year follow-up
allowed us to examine the direction of the association between
inflammatory biomarkers and depressive symptoms. Further-
more, we controlled for several confounding factors, which
can influence the association between inflammatory markers
and depression. Several limitations of our study need also to
be addressed. First, our study was restricted to older popula-
tion of men and women, and thus, our findings cannot be
generalized for the younger population. A second limitation
was the fact that we excluded participants who were on anti-
depressants, and thus, the findings might be not generalizable
for patients more severely ill and with clinical depression.
Finally, we do not have repeated measures of inflammatory
cytokines (IL-6, ACT and CRP) and therefore could not ana-
lyse whether long-term exposure to high levels of inflamma-
tory markers are associated with depression.
To conclude, our findings indicate that inflammatory bio-
markers IL-6 and CRP are longitudinally associated with per-
sistence and incident depressive symptoms in older men and
women, after adjustment for socio-demographic and health
characteristics. Inflammation seems to distinguish a particular
group of people who may benefit from preventive therapies.
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